Irreversible Electroporation Versus Radiofrequency Ablation for Malignant Hepatic Tumor: A Prospective Single-center Double-arm Trial

Overview

Journal J Interv Med

Specialty General Medicine

Date 2022 Aug 8

PMID 35936662

Authors

Boyu Liu

Dianxun Fu

Yong Fan

Zhe Wang

Xu Lang

Affiliations

Soon will be listed here.

Abstract

Objective: Irreversible electroporation (IRE) is a nonthermal ablation technique for the treatment of malignant liver tumors. IRE has demonstrated efficacy and safety in the treatment of malignant liver tumors and its unique advantages in the treatment of nearby vascular lesions. This study aimed to compare the efficacy, safety, and intermediate-term outcomes of IRE and radiofrequency (RF) therapy in malignant liver tumors.

Methods: Twenty-four patients with primary or secondary liver malignancies were included in this prospective, double-arm clinical trial. Patients were randomly divided into the IRE and RF groups. The primary outcome was the efficacy (local ablation control evaluation at 90 days). The secondary outcomes were safety (procedure-related complications at ≤ 90 days) and intermediate-term survival (at 24 months).

Results: The ablation assessment at 90 days after surgery with mRECIST for IRE versus RF were 70%, 20%, 0%, and 10% versus 92.9%, 7.1%, 0%, and 0% (CR, PR, SD, and PD, respectively). The complication rates of IRE versus RF with Clavien-Dindo classification were 16.7%, 25%, 0%, 8.3%, and 8.3% versus 8.3%, 50%, 0%, 0%, and 0% (Grade I, II, III, IV, and V, respectively). The average overall survival (OS) was 17.55 months in the IRE group (95% CI 15.13-22.37) and 18.75 months in the RF group (95% CI 12.48-22.61). There was no statistical difference between the IRE and RF groups in terms of efficacy (p = 0.48), safety(p = 0.887), or 24-month OS (p = 0.959).

Conclusions: IRE ablation revealed similar efficacy and safety in a short-term follow-up, and similar OS in mid-term survival as RF ablation in treating malignant hepatic tumors.

Citing Articles

Irreversible Electroporation of the Hepatobiliary System: Current Utilization and Future Avenues.

Narayanan G, Koethe Y, Gentile N Medicina (Kaunas). 2024; 60(2).

PMID: 38399539 PMC: 10890312. DOI: 10.3390/medicina60020251.

References

Niessen C, Thumann S, Beyer L, Pregler B, Kramer J, Lang S . Percutaneous Irreversible Electroporation: Long-term survival analysis of 71 patients with inoperable malignant hepatic tumors. Sci Rep. 2017; 7:43687. PMC: 5339813. DOI: 10.1038/srep43687. View

Bulvik B, Rozenblum N, Gourevich S, Ahmed M, Andriyanov A, Galun E . Irreversible Electroporation versus Radiofrequency Ablation: A Comparison of Local and Systemic Effects in a Small-Animal Model. Radiology. 2016; 280(2):413-24. DOI: 10.1148/radiol.2015151166. View

Baumler W, Sebald M, Einspieler I, Schicho A, Schaible J, Wiggermann P . Evaluation of Alterations to Bile Ducts and Laboratory Values During the First 3 Months After Irreversible Electroporation of Malignant Hepatic Tumors. Cancer Manag Res. 2020; 12:8425-8433. PMC: 7507879. DOI: 10.2147/CMAR.S261838. View

Niessen C, Beyer L, Pregler B, Dollinger M, Trabold B, Schlitt H . Percutaneous Ablation of Hepatic Tumors Using Irreversible Electroporation: A Prospective Safety and Midterm Efficacy Study in 34 Patients. J Vasc Interv Radiol. 2016; 27(4):480-6. DOI: 10.1016/j.jvir.2015.12.025. View

Davalos R, Mir I, Rubinsky B . Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005; 33(2):223-31. DOI: 10.1007/s10439-005-8981-8. View

Wendler J, Fischbach K, Ricke J, Jurgens J, Fischbach F, Kollermann J . Irreversible Electroporation (IRE): Standardization of Terminology and Reporting Criteria for Analysis and Comparison. Pol J Radiol. 2016; 81:54-64. PMC: 4760650. DOI: 10.12659/PJR.896034. View

Niessen C, Beyer L, Haimerl M, Schicho A, Stroszczynski C, Wiggermann P . Percutaneous irreversible electroporation of hepatocellular carcinoma: Contrast-enhanced ultrasound-findings during 1-year follow-up. Clin Hemorheol Microcirc. 2018; 72(1):85-93. DOI: 10.3233/CH-180449. View

Lee Y, Lu D, Osuagwu F, Lassman C . Irreversible electroporation in porcine liver: short- and long-term effect on the hepatic veins and adjacent tissue by CT with pathological correlation. Invest Radiol. 2012; 47(11):671-5. DOI: 10.1097/RLI.0b013e318274b0df. View

Narayanan G, Bhatia S, Echenique A, Suthar R, Barbery K, Yrizarry J . Vessel patency post irreversible electroporation. Cardiovasc Intervent Radiol. 2014; 37(6):1523-9. DOI: 10.1007/s00270-014-0988-9. View

10.

Clavien P, Barkun J, De Oliveira M, Vauthey J, Dindo D, Schulick R . The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009; 250(2):187-96. DOI: 10.1097/SLA.0b013e3181b13ca2. View

11.

Ben-David E, Appelbaum L, Sosna J, Nissenbaum I, Goldberg S . Characterization of irreversible electroporation ablation in in vivo porcine liver. AJR Am J Roentgenol. 2011; 198(1):W62-8. DOI: 10.2214/AJR.11.6940. View

12.

Faroja M, Ahmed M, Appelbaum L, Ben-David E, Moussa M, Sosna J . Irreversible electroporation ablation: is all the damage nonthermal?. Radiology. 2012; 266(2):462-70. DOI: 10.1148/radiol.12120609. View

13.

Freeman E, Cheung W, Kavnoudias H, Majeed A, Kemp W, Roberts S . Irreversible Electroporation For Hepatocellular Carcinoma: Longer-Term Outcomes At A Single Centre. Cardiovasc Intervent Radiol. 2020; 44(2):247-253. DOI: 10.1007/s00270-020-02666-4. View

14.

Dollinger M, Muller-Wille R, Zeman F, Haimerl M, Niessen C, Beyer L . Irreversible Electroporation of Malignant Hepatic Tumors--Alterations in Venous Structures at Subacute Follow-Up and Evolution at Mid-Term Follow-Up. PLoS One. 2015; 10(8):e0135773. PMC: 4535980. DOI: 10.1371/journal.pone.0135773. View

15.

Lencioni R, Llovet J . Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010; 30(1):52-60. DOI: 10.1055/s-0030-1247132. View

16.

Bhutiani N, Philips P, Scoggins C, McMasters K, Potts M, Martin R . Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford). 2016; 18(7):593-9. PMC: 4925804. DOI: 10.1016/j.hpb.2016.03.609. View

17.

Distelmaier M, Barabasch A, Heil P, Kraemer N, Isfort P, Keil S . Midterm Safety and Efficacy of Irreversible Electroporation of Malignant Liver Tumors Located Close to Major Portal or Hepatic Veins. Radiology. 2017; 285(3):1023-1031. DOI: 10.1148/radiol.2017161561. View

18.

Freeman E, Cheung W, Ferdousi S, Kavnoudias H, Majeed A, Kemp W . Irreversible electroporation versus radiofrequency ablation for hepatocellular carcinoma: a single centre propensity-matched comparison. Scand J Gastroenterol. 2021; 56(8):942-947. DOI: 10.1080/00365521.2021.1930145. View

19.

Chen M, Li J, Zheng Y, Guo R, Liang H, Zhang Y . A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243(3):321-8. PMC: 1448947. DOI: 10.1097/01.sla.0000201480.65519.b8. View

20.

Kuipers E, Grady W, Lieberman D, Seufferlein T, Sung J, Boelens P . Colorectal cancer. Nat Rev Dis Primers. 2016; 1:15065. PMC: 4874655. DOI: 10.1038/nrdp.2015.65. View